NCT00358384View on ClinicalTrials.gov

Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 26, 2005

Primary Completion Date

February 24, 2006

Study Completion Date

February 24, 2006

Conditions
Psoriasis
Interventions
DRUG

Pazopanib

Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.

DRUG

Pazopanib vehicle

Pazopanib vehicle will be given to subjects.

DRUG

Betamethasone valerate

Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.

DRUG

Calcipotriol

Calcipotriol ointment with 0.005 percent concentration will be given to subjects.

Trial Locations (1)

75015

GSK Investigational Site, Paris

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00358384 - Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 | Biotech Hunter | Biotech Hunter